Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Lilly USA, LLC.

For further information concerning Lilly grant funding visit

Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination

Release Date: June 16, 2021
Expiration Date: June 16, 2022

Activity Overview

This educational activity is an archive of the live virtual presentation held on June 15, 2021.

For more information about this educational activity, please click here.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.

For further information concerning Lilly grant funding visit

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the impact of genetic testing in diagnosis and treatment decision-making in thyroid cancer
  • Evaluate the clinical profiles of current and emerging targeted therapies for the treatment of patients with RAI-refractory DTC and advanced MTC
  • Translate results from landmark trials evaluating targeted agents in thyroid cancer into personalized treatment plans with a focus on multidisciplinary care optimization
  • Implement proactive strategies to identify and manage treatment-related toxicities in patients with RAI-refractory DTC and advanced MTC


Marcia S. Brose, MD, PhD
Marcia S. Brose, MD, PhD
Professor of Medicine and Otorhinolaryngology
Head and Neck Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA


Jill Gilbert, MD
Jill Gilbert, MD
Professor of Medicine (Hematology/Oncology)
Director, Hematology/Oncology Fellowship Program
Vanderbilt University Medical Center
Nashville, TN


Jennifer JD Morrissette, PhD
Jennifer JD Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Francis Paul Worden, MD
Francis Paul Worden, MD
Clinical investigator
Multidisciplinary Head and Neck Oncology
Multidisciplinary Lung Cancer
University of Michigan Rogel Cancer Center
Ann Arbor, MI

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By